Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Biontech Se ADR
(NQ:
BNTX
)
122.68
+2.88 (+2.40%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 4, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Biontech Se ADR
< Previous
1
2
3
4
5
6
7
8
9
Next >
BioNTech Highlights AI Capabilities and R&D Use Cases at Inaugural AI Day
October 01, 2024
From
BioNTech SE
Via
GlobeNewswire
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European Union
September 20, 2024
From
Pfizer Inc.
Via
Business Wire
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European Union
September 20, 2024
From
BioNTech SE
Via
GlobeNewswire
BioNTech to Host AI Day as an Edition of its Innovation Series on October 1, 2024
September 17, 2024
From
BioNTech SE
Via
GlobeNewswire
BioNTech to Present Clinical Data Updates Across mRNA and Immunomodulatory Oncology Portfolio at ESMO Congress 2024
September 05, 2024
From
BioNTech SE
Via
GlobeNewswire
New Research Reveals Emergence of New Variants of Coronavirus to Boost COVID-19 Therapeutics Market Growth
September 04, 2024
EQNX::TICKER_START (NASDAQ:SBFM),(NASDAQ:NVAX),(NASDAQ:RGNX),(NASDAQ:BNTX),(NYSE:ABBV) EQNX::TICKER_END
Via
FinancialNewsMedia
Exposures
COVID-19
New Research Reveals Emergence of New Variants of Coronavirus to Boost COVID-19 Therapeutics Market Growth
September 04, 2024
From
FN Media Group LLC
Via
GlobeNewswire
Pfizer and BioNTech Receive U.S. FDA Approval & Authorization for Omicron KP.2-adapted COVID-19 Vaccine
August 22, 2024
From
Pfizer Inc.
Via
Business Wire
Pfizer and BioNTech Receive U.S. FDA Approval & Authorization for Omicron KP.2-adapted COVID-19 Vaccine
August 22, 2024
From
BioNTech SE
Via
GlobeNewswire
Moderna Dips on Q2 Earnings But Can It Rip on a Short Squeeze?
August 19, 2024
Biotechnology company Moderna Inc. (NASDAQ: MRNA) stock rocked investors with a 30% drop following its second-quarter 2024 earnings release.
Via
MarketBeat
Exposures
COVID-19
Product Safety
Pfizer and BioNTech Provide Update on mRNA-based Combination Vaccine Program Against Influenza and COVID-19 in Individuals 18-64 Years of Age
August 16, 2024
From
Pfizer Inc.
Via
Business Wire
Pfizer and BioNTech Provide Update on mRNA-based Combination Vaccine Program Against Influenza and COVID-19 in Individuals 18-64 Years of Age
August 16, 2024
From
BioNTech SE
Via
GlobeNewswire
Novavax Plunges on Earnings Miss: Falling Knife or Buying Opp?
August 12, 2024
Novavax Inc. (NASDAQ: NVAX) is a biotechnology company that focuses on developing and commercializing vaccines for serious infectious diseases.
Via
MarketBeat
Exposures
COVID-19
BioNTech Announces Second Quarter 2024 Financial Results and Corporate Update
August 05, 2024
From
BioNTech SE
Via
GlobeNewswire
BioNTech Announces Positive Topline Phase 2 Results for mRNA Immunotherapy Candidate BNT111 in Patients with Advanced Melanoma
July 30, 2024
From
BioNTech SE
Via
GlobeNewswire
BioNTech to Report Second Quarter 2024 Financial Results and Corporate Update on August 5, 2024
July 22, 2024
From
BioNTech SE
Via
GlobeNewswire
Biotech Stock Breakout: IBB Eyes Resistance with Amgen and Vertex
July 02, 2024
The biotech sector (IBB) is trading just 3% away from its 52-week high and a significant resistance level, suggesting a potential breakout.
Via
MarketBeat
Topics
ETFs
Exposures
COVID-19
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron JN.1-adapted COVID-19 Vaccine in the European Union
June 27, 2024
From
Pfizer Inc.
Via
Business Wire
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron JN.1-adapted COVID-19 Vaccine in the European Union
June 27, 2024
From
BioNTech SE
Via
GlobeNewswire
BioNTech and DualityBio Receive FDA Fast Track Designation for Antibody-Drug Conjugate Candidate BNT324/DB-1311 in Prostate Cancer
June 24, 2024
From
BioNTech SE
Via
GlobeNewswire
Meme Stocks Surge Led by ‘Roaring Kitty’ and Social Media Buzz on Reddit (NYSE: RDDT), GME, DYAI, AMC, PRSO, NVAX
June 06, 2024
Via
AB Newswire
Dyadic International Inc. (NASDAQ: DYAI) Hits New 52-Week High Amidst Golden Cross, Bullish Swing Patterns and Bird Flu Concerns
June 06, 2024
Via
AB Newswire
Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)
June 01, 2024
From
Genmab A/S
Via
Business Wire
Dyadic International Inc. (DYAI): Bird Flu Vaccine Development Amid Rising Pandemic Concerns
May 30, 2024
Via
AB Newswire
Exposures
COVID-19
BioNTech and CEPI Expand Partnership to Strengthen Africa’s mRNA Vaccine Ecosystem
May 29, 2024
From
BioNTech SE
Via
GlobeNewswire
Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)
June 01, 2024
From
BioNTech SE
Via
GlobeNewswire
BioNTech to Present Clinical Data Updates for Next-Generation Immunotherapy Candidates at the ASCO Annual Meeting 2024
May 21, 2024
From
BioNTech SE
Via
GlobeNewswire
BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2024
May 17, 2024
From
BioNTech SE
Via
GlobeNewswire
BioNTech Announces First Quarter 2024 Financial Results and Corporate Update
May 06, 2024
From
BioNTech SE
Via
GlobeNewswire
BioNTech to Report First Quarter 2024 Financial Results and Corporate Update on May 6, 2024
April 22, 2024
From
BioNTech SE
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.